Simple Summary Despite breakthroughs in medicine, cancer remains one of the most feared
diseases. Traditionally, chemotherapies have been the treatment of choice. However …

Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth.
Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Abstract Background N6-methyladenosine (m6A) methylation, a well-known modification
with new epigenetic functions, has been reported to participate in the tumorigenesis of …

Despite advances in the treatment of cancers through surgical procedures and new
pharmaceuticals, the treatment of hepatocellular carcinoma (HCC) remains challenging as …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Background CD8+ T cells differentiate into exhausted status within tumors, including
hepatocellular carcinoma (HCC), which constitutes a solid barrier to effective anti-tumor …

Background & Aims Neutrophils can either promote or inhibit tumor progression, depending
on the tumor microenvironment, via release of cytokines. Neither the factors produced by …

Hepatocellular carcinoma (HCC) is the most frequent primary liver malignancy and the third
cause of cancer-related death in the Western Countries. The well-established causes of …

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …